Curosurf

Curosurf (Poractant Alfa) is a natural surfactant used for respiratory support in premature infants. This product, manufactured by Chiesi Limited, aids in lung function and is administered via endotracheal tube.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. It works by replacing the natural surfactant in the lungs, which helps the lungs expand more easily. This medication is crucial for infants who have difficulty breathing due to underdeveloped lungs.

Curosurf helps to improve lung function by reducing the surface tension in the alveoli, allowing them to stay open and facilitate breathing. This can lead to improved oxygenation and reduced need for mechanical ventilation in premature infants.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is essential to follow proper handling and storage guidelines to maintain its efficacy. Always consult a healthcare provider for specific instructions and precautions.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications or treatments the infant is receiving. Interactions with other drugs are not commonly reported, but professional advice should be sought to ensure safety.